专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08242156B2 Linked dibenzimidazole derivatives 有权
公开(公告)号：US08242156B2
公开(公告)日：2012-08-14
申请号：US12702802
申请日：2010-02-09
申请人： Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
发明人： Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
IPC分类号： A61K31/4184 , C07D403/04 , C07D235/14
CPC分类号： C07F9/65583 , A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/422 , A61K31/423 , A61K31/4245 , A61K31/427 , A61K31/444 , A61K31/454 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C12N2770/24211
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

2. 发明申请

US20110189129A1 HEPATITIS C VIRUS INHIBITORS 有权
标题翻译： HEPATITIS C病毒抑制剂
公开(公告)号：US20110189129A1
公开(公告)日：2011-08-04
申请号：US13013212
申请日：2011-01-25
申请人： Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Hui Cao , Yat Sun Or
发明人： Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Hui Cao , Yat Sun Or
IPC分类号： A61K38/21 , C07D487/14 , A61K31/4188 , A61K31/7056 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/41 , A61K31/427 , A61K31/675 , A61K31/422 , A61K31/439 , A61K31/4196 , A61K31/4245 , A61K31/506 , A61P31/12 , C12N7/04 , A61K39/12 , A61P37/04 , A61P1/16 , A61P31/18 , A61K38/19
CPC分类号： C07D498/18 , C07D519/00 , C07F9/6561
摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B—W (I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明公开了式（I）的化合物及其药学上可接受的盐，酯或前药：抑制含RNA病毒，特别是丙型肝炎病毒（HCV）的Q-G-A-L-B-W（I）因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

3. 发明申请

US20110064695A1 HEPATITIS C VIRUS INHIBITORS 有权
标题翻译： HEPATITIS C病毒抑制剂
公开(公告)号：US20110064695A1
公开(公告)日：2011-03-17
申请号：US12879025
申请日：2010-09-10
申请人： Yao-Ling Qiu , Ce Wang , Lu Ying , Xiaowen Peng , Yat Sun Or
发明人： Yao-Ling Qiu , Ce Wang , Lu Ying , Xiaowen Peng , Yat Sun Or
IPC分类号： A61K31/4178 , C07D403/14 , C07D401/14 , A61K31/444 , C07D405/14 , A61K31/4545 , C07D413/14 , A61K31/5377 , A61K31/496 , C07D417/14 , A61K31/427 , A61K31/506 , A61K38/21 , A61P31/14
CPC分类号： C07D233/64 , A61K31/4178 , A61K31/427 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K38/21 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D473/00 , C07D487/04 , C07D487/08 , C07F9/65583 , C12N2770/24211 , A61K2300/00
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
摘要翻译：本发明公开了式（I）化合物或其药学上可接受的盐，酯或前药：其抑制含RNA病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上文所示的新的抗病毒化合物，包含这些化合物的药物组合物，以及用于治疗或预防需要用所述化合物治疗的受试者中的病毒（特别是HCV）感染的方法。

4. 发明申请

US20100260715A1 HEPATITIS C VIRUS INHIBITORS 有权
标题翻译： HEPATITIS C病毒抑制剂
公开(公告)号：US20100260715A1
公开(公告)日：2010-10-14
申请号：US12714576
申请日：2010-03-01
申请人： Yat Sun Or , Ce Wang , Lu Ying , Xiaowen Peng , Yao-Ling Qiu
发明人： Yat Sun Or , Ce Wang , Lu Ying , Xiaowen Peng , Yao-Ling Qiu
IPC分类号： A61K31/397 , C07D471/04 , A61K31/437 , C07D403/14 , A61K31/497 , C07D413/14 , A61K31/5377 , A61K31/506 , A61K38/21 , A61K38/19 , A61K39/00 , A61P31/12
CPC分类号： C07D401/14 , A61K38/212 , A61K38/215 , A61K38/217 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , A61K2300/00
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明公开了式（I）化合物或其药学上可接受的盐，酯或前药：其抑制含RNA病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

5. 发明申请

US20100135960A1 ANTIVIRAL ACYLSULFONAMIDE DERIVATIVES 审中-公开
标题翻译：抗病毒酰胺酰胺衍生物
公开(公告)号：US20100135960A1
公开(公告)日：2010-06-03
申请号：US12619974
申请日：2009-11-17
申请人： Yat Sun Or , Lu Ying , Ce Wang , Xiaowen Peng , Yao-Ling Qiu
发明人： Yat Sun Or , Lu Ying , Ce Wang , Xiaowen Peng , Yao-Ling Qiu
IPC分类号： A61K38/21 , A61K39/00 , A61K38/19 , A61K31/4439 , A61K31/427 , A61K31/422 , C07D401/02 , C07D417/02 , C07D413/02 , A61P31/14
CPC分类号： C07D417/14 , A61K38/21 , C07D231/12 , C07D401/12 , C07D413/12 , C07D417/12 , A61K2300/00
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
摘要翻译：本发明公开了式（I）化合物或其药学上可接受的盐，酯或前药：其抑制含RNA病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上文所示的新的抗病毒化合物，包含这些化合物的药物组合物，以及用于治疗或预防需要用所述化合物治疗的受试者中的病毒（特别是HCV）感染的方法。

6. 发明授权

US08188132B2 Linked dibenzimidazole derivatives 有权
标题翻译：连接的二苯并咪唑衍生物
公开(公告)号：US08188132B2
公开(公告)日：2012-05-29
申请号：US12702692
申请日：2010-02-09
申请人： Yat Sun Or , Ce Wang , Xiaowen Peng , Lu Ying , Yao-Ling Qiu
发明人： Yat Sun Or , Ce Wang , Xiaowen Peng , Lu Ying , Yao-Ling Qiu
IPC分类号： A61K31/4184 , C07D403/04 , C07D235/14
CPC分类号： A61K31/4184 , A61K31/427 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5377 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明公开了式（I）化合物或其药学上可接受的盐，酯或前药：其抑制含RNA病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

7. 发明申请

US20120076755A1 Hepatitis C Virus Inhibitors 有权
标题翻译：丙型肝炎病毒抑制剂
公开(公告)号：US20120076755A1
公开(公告)日：2012-03-29
申请号：US13252818
申请日：2011-10-04
申请人： Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Hui Cao , Yat Sun Or
发明人： Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Hui Cao , Yat Sun Or
IPC分类号： A61K31/4188 , A61K31/424 , A61K31/4439 , A61K31/454 , A61K31/5377 , A61P31/14 , A61P37/02 , A61K38/21 , A61K39/12 , A61K31/4196 , A61K31/427 , A61P1/16 , A61P29/00 , A61P31/18 , C12N7/06 , C07D487/16
CPC分类号： A61K31/415 , A61K31/4188 , A61K31/4196 , A61K31/424 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/5377 , A61K45/06 , C07D471/22 , C07D487/18 , C07D487/22 , C07D498/18 , C07D498/22 , C07D513/18 , Y02A50/463 , A61K2300/00
摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B-W (I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明公开了式（I）化合物及其药学上可接受的盐，酯或前药：抑制含RNA病毒，特别是丙型肝炎病毒（HCV）的Q-G-A-L-B-W（I）因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

8. 发明申请

US20110064697A1 HEPATITIS C VIRUS INHIBITORS 有权
公开(公告)号：US20110064697A1
公开(公告)日：2011-03-17
申请号：US12879029
申请日：2010-09-10
申请人： Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
发明人： Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
IPC分类号： A61K31/506 , C07D403/14 , C07D413/14 , C07D401/14 , A61K31/5377 , A61K31/496 , A61K31/517 , A61K31/4439 , A61K31/4178 , A61K39/00 , A61K38/21 , A61K31/427 , A61P31/14 , C12N7/06
CPC分类号： C07D401/14 , A61K38/21 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C12N2770/24211
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

9. 发明申请

US20100221215A1 LINKED DIBENZIMIDAZOLE DERIVATIVES 有权
公开(公告)号：US20100221215A1
公开(公告)日：2010-09-02
申请号：US12702802
申请日：2010-02-09
申请人： Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
发明人： Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
IPC分类号： A61K31/4184 , C07D403/14 , C07D401/14 , A61K31/444 , C07D405/14 , C07D413/14 , A61K31/5377 , A61K31/454 , A61K31/496 , C07D417/14 , A61K31/427 , C07D409/14 , A61K31/4192 , C07F9/6558 , A61K31/685 , C07D487/08 , A61K31/423 , A61K31/4709 , A61K31/4196 , A61K31/506 , A61K31/4245 , A61K31/422 , A61K38/21 , A61K39/00 , C12N7/06 , A61P31/14 , A61P31/18
CPC分类号： C07F9/65583 , A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/422 , A61K31/423 , A61K31/4245 , A61K31/427 , A61K31/444 , A61K31/454 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C12N2770/24211
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

10. 发明申请

US20090274686A1 NUCLEOSIDE PHOSPHONATE DERIVATIVES 审中-公开
标题翻译：核苷酸磷酸酯衍生物
公开(公告)号：US20090274686A1
公开(公告)日：2009-11-05
申请号：US12434146
申请日：2009-05-01
申请人： Yat Sun Or , Lu Ying , Xiaowen Peng , Ce Wang , Yao-Ling Qiu
发明人： Yat Sun Or , Lu Ying , Xiaowen Peng , Ce Wang , Yao-Ling Qiu
IPC分类号： A61K31/7064 , C07H19/20 , C07H19/10 , A61K31/7076 , A61K39/395 , A61P35/00 , A61P31/12
CPC分类号： C07H19/10 , C07H19/20
摘要： The present invention discloses compounds of formula (I) or (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.
摘要翻译：本发明公开了式（I）或（II）的化合物或其药学上可接受的盐，酯或前药：其特别是通过HIV，HCV或HBV抑制，预防或治疗异常的细胞增殖和/或病毒感染。因此，本发明的化合物干扰病毒的复制循环，也可用作抗病毒剂，或干扰宿主细胞生物化学过程，也可用作抗增殖剂。本发明还涉及药物组合物，其包含用于给患有病毒感染和/或细胞增殖的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的病毒感染和/或细胞增殖的方法。本发明涉及上文所述的新的抗病毒/抗增殖化合物，包含这些化合物的药物组合物，以及用于治疗或预防需要用所述化合物治疗的受试者的病毒感染的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式